Loading...
XSHG
603538
Market cap1.50bUSD
Oct 09, Last price  
28.45CNY
1D
-3.43%
1Q
-7.87%
IPO
114.65%
Name

Ningbo Menovo Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHG:603538 chart
P/E
94.60
P/S
6.43
EPS
0.30
Div yield, %
0.17%
Shrs. gr., 5y
1.14%
Rev. gr., 5y
4.72%
Revenues
1.50b
+9.49%
490,242,539486,647,014501,727,460636,304,955597,166,228578,087,830605,320,592848,961,5181,180,205,3241,193,373,2181,258,147,7091,456,982,4411,216,499,2841,372,855,2721,503,122,563
Net income
102m
+53.02%
69,334,97460,609,61569,005,23472,730,06277,020,19478,843,44144,677,40496,349,251150,904,877155,962,820142,526,370338,855,54111,585,59866,806,630102,229,352
CFO
158m
+61.54%
038,105,479149,207,27875,215,446133,418,224117,244,11880,153,53446,595,179179,751,928251,611,239220,628,551276,951,7469,133,09897,537,045157,562,759
Dividend
Jul 09, 20260.155 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ningbo Menovo Pharmaceutical Co., Ltd. operates across the full spectrum of pharmaceutical activities, encompassing the research, development, production, and distribution of medicinal products. Their extensive product line features Active Pharmaceutical Ingredients (APIs), intermediate chemicals, and finished drug formulations. These offerings are designed to address a wide range of therapeutic areas, including cardiovascular, central nervous system, respiratory, oncological, anti-infective, digestive, and geriatric disorders, as well as antiviral treatments. The company commenced operations in 2004 and maintains its principal place of business in Ningbo, China.

Key people

Gaofeng Ying
Finance Director, Secretary of the Board, Director · since 2021
Chengzhi Yao
Chairman of the Board, General Manager · since 2018
Jian Xu
Deputy General Manager · since 2019
Fang Yao
Director · since 2021
Hongjun Bei
Independent Director · since 2024
Jie Wei
Independent Director · since 2024
IPO date
Apr 07, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT